W
W. L. Whitter
Researcher at United States Military Academy
Publications - 7
Citations - 1537
W. L. Whitter is an academic researcher from United States Military Academy. The author has contributed to research in topics: Diastereomer & Receptor. The author has an hindex of 5, co-authored 7 publications receiving 1437 citations. Previous affiliations of W. L. Whitter include Merck & Co..
Papers
More filters
Journal ArticleDOI
Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists
Ben E. Evans,Kenneth E. Rittle,Mark G. Bock,Robert M. DiPardo,Roger M. Freidinger,W. L. Whitter,George F. Lundell,Daniel F. Veber,Paul S. Anderson,Raymond S.L. Chang,Victor J. Lotti,D. J. Cerino,Tsing-Bau Chen,Paul J. Kling,K. A. Kunkel,James P. Springer,J. Hirshfield +16 more
TL;DR: 3-(Acylamino)-5-phenyl-2H-1,4-benzodiazepines, antagonists of the peptide hormone cholecystokinin (CCK), are described, and the method of development of these compounds is discussed in terms of its relevance to the general problem of drug discovery.
Journal ArticleDOI
Methods for Drug Discovery: Development of Potent, Selective, Orally Effective Cholecystokinin Antagonists.
Ben E. Evans,Kenneth E. Rittle,Mark G. Bock,Robert M. DiPardo,Roger M. Freidinger,W. L. Whitter,George F. Lundell,Daniel F. Veber,Paul S. Anderson,Raymond S.L. Chang,Victor J. Lotti,D. J. Cerino,Tsing-Bau Chen,Paul J. Kling,K. A. Kunkel,James P. Springer,J. Hirshfield +16 more
TL;DR: In this article, 3.3-(Acylamino)-5-phenyl-2H-1,4-benzodiazepines, antagonists of the peptide hormone cholecystokinin (CCK), are described.
Journal ArticleDOI
A new amine resolution method and its application to 3-aminobenzodiazepines
Kenneth E. Rittle,Ben E. Evans,Mark G. Bock,Robert M. DiPardo,W. L. Whitter,Carl F. Homnick,Daniel F. Veber,Roger M. Freidinger +7 more
TL;DR: In this paper, a new method for the resolution of amines and its application to 3-aminobenzodiazepines was described, which involves the synthesis and separation of a pair of phenylalanyl amide diastereomers followed by removal of phenYLalanine via the Edman degradation to give the individual enantiomers of 1 with high chiral purities.
Journal ArticleDOI
Development of 1,4-Benzodiazepine Cholecystokinin Type B Antagonists.
Mark G. Bock,Robert M. DiPardo,B. E. Evans,Kenneth E. Rittle,W. L. Whitter,V. M. Garsky,Kevin F. Gilbert,James L. Leighton,K. L. Carson,E. C. Mellin,D. F. Veber,R. S. L. Chang,Victor J. Lotti,Stephen B. Freedman,A. J. Smith,Shil Patel,P. S. Anderson,Roger M. Freidinger +17 more
Journal ArticleDOI
Design of Nonpeptidal Ligands for a Peptide Receptor: Cholecystokinin Antagonists.
B. E. Evans,Kenneth E. Rittle,Mark G. Bock,Robert M. DiPardo,Roger M. Freidinger,W. L. Whitter,N. P. Gould,G. F. Lundell,Carl F. Homnick,D. F. Veber,P. S. Anderson,R. S. L. Chang,Victor J. Lotti,D. J. Cerino,Tsing-Bau Chen,P. J. King,K. A. Kunkel,J. P. Springer,J. Hirshfield +18 more
TL;DR: Coupling of the benzophenones (I) with D-tryptophan methyl ester hydrochloride (II) gives the benzodiazepinones (III) as mentioned in this paper.